Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-09-20
2010-02-09
Ouspenski, Ilia (Department: 1644)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C435S320100, C435S252300, C435S455000, C435S069100
Reexamination Certificate
active
07659384
ABSTRACT:
Fully human antibodies and antigen-binding portions thereof that bind to human 4-1BB and that allow binding of human 4-1BB to a human 4-1BB ligand. In one aspect, the antibody is an IgG4 antibody. Also provided is a method for treating a disease in a subject comprising administering a therapeutically effective amount of the antibody to said subject.
REFERENCES:
patent: 6458934 (2002-10-01), Hong et al.
patent: 6569997 (2003-05-01), Kwon
patent: 7288638 (2007-10-01), Jure-Kunkel et al.
patent: 2108401 (1995-03-01), None
patent: WO1994/26290 (1994-11-01), None
patent: WO1995/07984 (1995-03-01), None
patent: WO1996/32495 (1996-01-01), None
patent: WO1996/29348 (1996-09-01), None
patent: WO 97/33898 (1997-09-01), None
patent: WO 98/16249 (1998-04-01), None
patent: WO 99/36093 (1999-07-01), None
patent: WO 99/44629 (1999-09-01), None
patent: WO 00/29445 (2000-05-01), None
patent: WO 02/36141 (2002-05-01), None
patent: WO 03/006632 (2003-01-01), None
patent: WO 03/031474 (2003-04-01), None
patent: WO 03/049755 (2003-06-01), None
patent: WO 03/083069 (2003-10-01), None
patent: WO 03/084999 (2003-10-01), None
patent: WO 2004/006853 (2004-01-01), None
patent: WO 2004/010947 (2004-02-01), None
patent: WO 2004/019866 (2004-03-01), None
patent: WO 2004/055513 (2004-07-01), None
patent: WO 2004/093831 (2004-11-01), None
Abbas, A., et al., “T Lymphocyte Antigen Recognition and Activation”, Cellular and Molecular Immunology, Chapter 7 Third Edition, pp. 139-170 (1997).
Alderson, M.R., et al., “Molecular and biological characterization of human 4-1BB and its ligand”, Eur. J. Immunol., vol. 24, pp. 2219-2227 (1994).
Angal, S., et al., “A single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric Mouse/Human (IgG4) Antibody”, Molecular Immunology, vol. 30(1), pp. 105-108 (1993).
Antonia, S. et al., “Current developments of immunotherapy in the clinic”, Current Opinion in Immunology, vol. 16, pp. 130-136 (2004).
Ashkenazi, A., Nature, “Targeting Death and Decoy Receptors of the Tumour-Necrosis Factor Superfamily”, Nature, vol. 2, pp. 420-430 (2002).
Bansal-Pakala, P. et al., “Defective T Cell Priming Associated with Aging Can Be Rescued by Signaling Through 4-1BB (CD137)”, The Journal of Immunology, vol. 169, pp. 5005-5009 (2002).
Bassi, P.F., “BCG (Bacillusof Calmette Guerin) therapy of high-risk superficial bladder cancer”, Surgical Oncology, vol. 11, pp. 77-83, (2002).
Bertley, F., et al., “Control of Simian/Human Immunodeficiency Virus Viremia and Disease Progression after IL-2-Augmented DNA-Modified Vaccinia Virus Ankara Nasal Vaccination in Nonhuman Primates”, The Journal of Immunology, vol. 172, pp. 3745-3757, (2004).
Bu, Z., et al., “Enhanced cellular immune response against SIV Gag induced by immunization with DNA vaccines expressing assembly and release-defective SIV Gag proteins”, Virology, vol. 309, pp. 272-281, (2003).
Chambers, C. et al., Current Opinion in Immunology, “Co-Stimulation in T-Cell Responses”, vol. 19, pp. 396-404 (1997).
Chothia, C. et. al., J. Mol. Biol., “Canonical Structures for the Hypervariable Regions of Immunoglobulins”, vol. 196, pp. 901-917 (1987).
Cooper, D., “4-1BB (CD137) controls the clonal expansion and survival of CD8 T cells in vivo but does not contribute to the development of cytotoxicity”, Eur. J. Immunology, vol. 32, pp. 521-529 (2002).
DeBenedette, M. et al., Journal of Immunology, “Costimulation of CD28 T Lymphocytes by 4-1BB Ligand”, vol. 158, pp. 551-559 (1997).
DeBenedette, M., et al., “Analysis of 4-1BB Ligand (4-1 BBL)-Deficient Mice and of Mice Lacking Both 4-1BBL and CD28 Reveals a Role for 4-1BBL in Skin Allograft Rejection and in the Cytotoxic T Cell Response to Influenza Virus”, pp. 4833-4841 (1999).
Dranoff, G., et al., “Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity”, Proc. Nat'l. Acad. Sci. USA, vol. 90, pp. 3539-3543, (1993).
Elder, D., Acta Oncologica, “Tumor Progression, Early Diagnosis and Prognosis of Melanoma”, vol. 38, pp. 535-547 (1999).
Fishman, M. et al., Expert Opin. Investig. Drugs, “Novel Therapies For High-Risk Superficial Bladder Cancer”, vol. 11, pp. 77-83 2002).
Foell, J., et al., “CD137-Mediated T Cell Co-Stimulation Terminates Existing Autoimmune Disease in SLE-Prone NZB/NZW F1 Mice”, N.Y. Acad. Sci., vol. 987, pp. 230-235 (2003).
Foote, J. et al., J.Mol. Biol., “Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops”, vol. 224, pp. 487-499 (1992).
Futagawa, T., et al., “Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells”, International Immunology, vol. 14, pp. 275-286, (2001).
Goodwin, R.G., et al., “Molecular cloning of a ligand for the inducible T cell gene 4-1BB: a member of an emerging family of cytokines with homology to tumor necrosis factor”, Eur. J. Immunol., vol. 23, pp. 2631-2641 (1993).
Gramaglia, I. et al., “Co-stimulation of antigen-specific CD4 T cells by 4-1BB ligand”, Eur. J. Immunol., vol. 30, pp. 293-402, (2000).
Guinn, B., et al., “4-1BBL Cooperates with B7-1 and B7-2 in Converting a B Cell Lymphoma Cell Line into a Long-Lasting Antitumor Vaccine”, The American Association of Immunologists, vol. 162 pp. 5003-5010, (1999).
Hakim, F.T., et al., “Aging, Immunity and Cancer”, Current Opinion in Immunology, vol. 16, pp. 151-156, (2004).
Halapi, E, “Oligoclonal T cells in human cancer”, Medical Oncology, vol. 15, pp. 203-211, (1998).
Hong, H.J., “A Humanized Anti-4-1BB Monoclonal Antibody Suppresses Antigen-Induced Humoral Immune Response in Nonhuman Primates”, Journal of Immunotherapy, vol. 23, pp. 613-621, (2000).
Hurtado, J. et al., “Potential Role of 4-1BB in T Cell Activation”, Journal of Immunology, vol. 155, pp. 3360-3367 (1995).
Hurtado, J.C., et al., “Signals Through 4-1BB Are Costimulatory to Previously Activated Splenic T Cells and Inhibit Activation-Induced Cell Death”, The American Association of Immunologists, pp. 2600-2609 (1997).
Jaffee, E.M. et al., “Novel Allogeneic Granulocyte-Macrophage Colony-Stimulating Factor-Secreting Tumor Vaccine for Pancreatic Cancer: A Phase I Trial of Safety and Immune Activation”, Journal of Clinical Oncology, vol. 19, No. 1, pp. 145-156 (2001).
Jones, P. et al., “Replacing the Complementary-Determining Regions in a Human Antibody With Those From a Mouse”, Nature, vol. 321, pp. 522-525 (1986).
Ju., S. et al., “A Functional Anti-Human 4-1BB Ligand Monoclonal Antibody that Enhances Proliferation of Monocytes by Reverse Signaling of 4-1BBL”, Hybridoma and Hybridomincs, vol. 22, No. 5, pp. 333-338, (2003).
Kearney, J. et al., Journal of Immunology, “A New Mouse Myeloma Cell Line That Has Lost Immunoglobulin Expression But Permits the Construction of Antibody-Secreting Hybrid Cell Lines”, vol. 123, No. 4, pp. 1548-1550 (1979).
Kim, J.J. et al., “Engineering Enhancement of Immune Responses to DNA-based Vaccines in a Prostate Cancer Model in Rhesus Macaques through the Use of Cytokine Gene Adjuvants”, Clinical Cancer Research, vol. 7, pp. 882s-889s, (2001).
Kim, J.J. “Induction of Immune responses and safety profiles in rhesus macaques immunized with a DNA vaccine expressing human prostate specific antigen”, Oncogene, vol. 20, pp. 4497-4506, (2001).
Kim, J.A. et al., “Divergent Effects of 4-1BB Antibodies on Antitumor Immunity and on Tumor-reactive T-Cell Generation”, Cancer Research, vol. 61, pp. 2031-2037, (2001).
Kim, N.W. et al., “Specific Association of Human Telomerase Activity with Immortal Cells and Cancer”, Science, vol. 266, pp. 2011-2015 (1994).
Kim, Y. et al
Ganguly Subinay
Halk Edward L.
Hefta Laura J.
Jure-Kunkel Maria
Santoro Marc
Bristol--Myers Squibb Company
Golian Paul D.
Ouspenski Ilia
LandOfFree
Polynucleotides encoding fully human antibodies against... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Polynucleotides encoding fully human antibodies against..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polynucleotides encoding fully human antibodies against... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183982